Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

93.09 +0.85 (+0.92%)
Streaming Delayed Price Updated: 12:07 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biontech Se ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
52 53 Next >
4 Analysts Have This to Say About BioNTech
Via Benzinga
7 Blue-Chip Stocks Sitting in the Sweet Spot
Although blue-chip stocks carry a reputation for being bulky and not exciting, these large enterprises can really move. 
Via InvestorPlace
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
Chinese health authorities approved CSPC Pharmaceuticals Group Ltd's (OTC: CSPCY) messenger RNA (mRNA) COVID-19 vaccine for emergency use authorization. 
Via Benzinga
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk. 
Via Benzinga
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders
Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans. 
Via Investor's Business Daily
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Price Over Earnings Overview: BioNTech
Via Benzinga
BioNTech Q4 2022 Earnings Conference Call On March 27, 2023 At 08:00 AM ET
Via Benzinga
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose
From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector. 
Via Benzinga
7 Stocks Set to Soar When the Market Recovers
Daring contrarians can bid up the danger with these intriguing market ideas. 
Via InvestorPlace
FDA Approves Pfizer/BioNTech's Bivalent COVID-19 Vaccine For Youngest Kids
Via Benzinga
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Tesla CEO Elon Musk has been a skeptic of the COVID-19 vaccines and highly critical of Dr. 
Via Benzinga
Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential
They're both facing the same fierce headwind, and it won't be going away soon. 
Via The Motley Fool
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
Via Benzinga
European Commission Keeps Mum On Talks Regarding Pfizer COVID-19 Vaccine Contract: Report
European Commission President Ursula von der Leyen remains silent on her dealings with Pfizer Inc (NYSE: PFE) regarding the EU's COVID-19 vaccine contract is hurting public trust. 
Via Benzinga
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Startling cancer vaccine results from Moderna may point to the next big thing in biotech. 
Via Investor's Business Daily
Pfizer/BioNTech Seek Expanded Approval For Its Updated COVID-19 Shot As Primary Series Vaccination
Via Benzinga
Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop
The company is doubling down on its vaccine success. 
Via The Motley Fool
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Shares crumbled after Moderna's flu shot outperformed in just one flu strain. 
Via Investor's Business Daily
Why Is Moderna (MRNA) Stock Down 5% Today?
If Moderna's new formulation works the latest failure will be a short-term hiccup. But MRNA stock also faces legal and PR challenges. 
Via InvestorPlace
Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
Via Benzinga
Is Novavax Stock a Buy With the New Normal for COVID?
The landscape has shifted dramatically in the COVID-19 vaccine market. 
Via The Motley Fool
The 3 Most Undervalued Growth Stocks for Your February Buy List
These undervalued growth stocks have the value and projected growth that investors seek when researching their next investment decisions. 
Via InvestorPlace
Better Buy: Novavax or BioNTech Stock?
The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot. 
Via The Motley Fool
The 7 Most Undervalued Biotech Stocks to Buy in February 2023
Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy. 
Via InvestorPlace
Why BioNTech And Moderna Shares Are Falling After Pfizer News
BioNTech SE - ADR (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) shares are trading lower Tuesday morning in sympathy with Pfizer Inc. (NYSE: 
Via Benzinga
$1,000 Invested In 4 Of The 5 Vaccine Developers Back When WHO Declared COVID-19 An Emergency Yielded Returns
The COVID-19 pandemic emerged in 2019 in China and spread to the rest of the globe in early 2020. Since then, the virus has caused more than 6.8 million deaths. 
Via Benzinga
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
The FDA's experts voted in favor of annual boosters on Thursday. 
Via Investor's Business Daily
Thursday Predictions: 3 Hot Stocks for Tomorrow
Airline stocks, credit card stocks, and vaccine stocks are our focus when it comes to the hot stocks for tomorrow. Here's why. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.